Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept quality-of-life study in diabetic macular edema
NL-OMON42719Phase 4Withdrawn
- Sponsor
- Syneos Health
- Start
- May 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Syneos Health. Primary endpoint: Change from baseline to Week 52 in NEI VFQ-25 total score. Planned start May 2015; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON42719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42719.